Further studies comparing cardiovascular disease and its main subtypes incidence before and after full implementation of SGLT2-i and GLP1-analogs in the clinical practice help to delineate their impact in a real-world setting. The gene discussed is SLC5A2; the disease is cardiovascular disorder.